Private beta · coming late 2026
BioKit Canvas turns scattered biopharma evidence into a living, source-backed view of companies, assets, trials, filings, ownership, and market signals, so investment, BD, and strategy teams build conviction without starting from scratch.
The problem
Biopharma strategy has two jobs running at once. The sprint: get smart on a new asset, target, company, readout, or deal context before the next meeting. The marathon: keep the competitive picture current as trials read out, partnerships form, filings land, and portfolios shift.
In theory, those jobs should compound. Every sprint should enrich the standing view. Every standing view should make the next sprint faster. In practice, the work resets: scattered databases, stale decks, buried memos, and source trails no one can fully reconstruct.
Today
Scattered sources
You subscribe to five platforms and none of them talk to each other: Cortellis for the pipeline, EDGAR for the filings, PubMed for the science, ClinicalTrials.gov for the trials. Then you paste it into a deck.
Slow synthesis
A competitive landscape takes two weeks by hand; a diligence memo takes a month with a consultant. By the time the deck is done, three trials have read out and two deals have closed.
Unsupported answers
ChatGPT hands you a hallucinated trial and a partnership that doesn't exist. You can't send that to a VP. You can't put it in front of a board.
Knowledge decay
Last quarter's deep dive is already stale, and the analyst who built the model has left the team.
With BioKit Canvas
Connected view
Pipeline, filings, science, and trials answered in one place, with no tab-hopping and no copy-paste.
Ready in minutes
Ask a question and get a sourced answer in minutes, not the days it takes to assemble by hand.
Defensible answers
Every claim links to a filing, trial, or paper, with a confidence score you can defend.
Living landscape
Canvas pulls from current sources, so analyses refresh as new filings and trial data land, instead of freezing the day you built them.
The workspace
Start with a real diligence question: a company, asset, readout, or deal.
Sourced fragments
ClinicalTrials.gov
mRNA-4157 Ph3 readout · 2026
SEC EDGAR
~$6.0B cash · ~$0.5B/qtr burn
13F · Form 4
institutions −4% QoQ
PubMed
5-yr melanoma data positive
Verdict
Catalyst-driven re-rate is plausible; readout timing is the swing factor.
Ask a diligence question...
Start with a real diligence question: a company, asset, readout, or deal.
Canvas is built around the way diligence actually unfolds: one question expands into companies, assets, mechanisms, trials, filings, ownership changes, publications, and market context.
Instead of switching between retrieval tools and rebuilding the synthesis by hand, Canvas assembles a sourced workspace around the question, then preserves the trail so the next analysis starts from what the organization already learned.
ExploreScreen the biotech universe.
Why BioKit Canvas
The hard part is not producing a summary. It is knowing what was checked, what changed, which sources conflict, and why the answer deserves confidence.
Canvas makes the basis of every answer inspectable, and keeps that picture current as the landscape moves, so the call you take to committee stays defensible.
Science and finance on one screen: pipeline next to SEC filings next to the stock. Neither Bloomberg nor Benchling can show you this.
Every answer shows its work: source links, provenance, and a 1–5 confidence score, so you can trace each claim back to a filing, trial, or paper instead of taking it on faith.
The deep dive that used to take an analyst two weeks, assembled in an afternoon, so your time goes to judgment instead of gathering.
Use cases
Get smart on this company before Monday's partner meeting.
Pipeline, ownership, catalysts, and comparable readouts in one sourced workspace.
What changed in this landscape since our last review?
New trials, filings, publications, partnerships, and market moves mapped against the prior view.
Is this asset differentiated enough to justify serious diligence?
Mechanism, endpoints, comparators, readouts, and competitive pressure connected to the decision.
Where is portfolio risk becoming concentrated?
Phase risk, catalyst timing, ownership exposure, and correlated readouts across the book.
FAQ